7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31 2009-12-31 2009-09-30 2009-06-30 2009-03-31 2008-12-31 2008-09-30 2008-06-30 2008-03-31 2007-12-31 2007-09-30 2007-06-30 2007-03-31 2006-12-31 2006-09-30 2006-06-30 2006-03-31 2005-12-31 2005-09-30 2005-06-30 2005-03-31 2004-12-31 2004-09-30 2004-06-30 2004-03-31 2003-09-30 
      
    		                                                                                        
      net income
    		193,578,000 184,848,000 159,616,000 139,861,000 117,973,000 226,116,000 37,317,000 85,518,000 1,041,000 81,178,000 40,028,000 -30,173,000 73,210,000 70,672,000 68,573,000 95,166,000 38,204,000 96,092,000 1,601,000 28,388,000 -32,040,000 66,821,000 48,612,000 68,743,000 97,452,000 79,042,000 75,775,000 360,089,000 126,630,000 87,494,000 115,857,000 38,489,000 81,382,000 17,656,000 16,700,000 35,123,000 -6,983,000 -37,015,000 -61,347,000 -43,641,000 -47,564,000 -43,362,000 -35,170,000 -57,953,000 -62,560,000 -73,410,000 -74,619,000 -70,746,000 -67,124,000 -62,161,000 -44,729,000 -52,193,000 -32,814,000 -36,487,000 -26,151,000    -27,490,000         -37,949,000 -38,507,000 -45,124,000 -41,274,000 -19,922,000 -13,696,000 -28,562,000 -24,201,000 -25,182,000 -25,197,000 -23,990,000 -27,123,000 -24,522,000 -22,775,000 -9,696,000 -27,411,000 -51,922,000   -28,843,000 -24,995,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                                                                                        
      depreciation and amortization
    		7,422,000 7,342,000 7,345,000          5,663,000            2,090,000 2,036,000 1,962,000 2,039,000 1,700,000 805,000 371,000 345,000 279,000 282,000 281,000 248,000 298,000 227,000 229,000 343,000 379,000 387,000 297,000 -623,000 1,921,000 595,000 498,000 765,000 754,000 786,000 842,000 1,646,000 1,431,000 1,407,000 1,233,000 1,787,000 1,106,000 2,000,000 1,929,000 2,267,000 2,403,000 2,801,000 3,072,000 3,037,000 3,117,000 3,155,000 3,286,000 3,405,000 3,261,000 3,297,000 3,264,000 3,142,000 2,847,000 2,384,000 2,757,000 3,524,000 3,893,000 4,360,000 4,313,000 4,115,000 4,298,000 4,078,000 4,178,000 4,173,000 3,967,000 4,097,000 4,478,000 4,180,000 
      impairment of long-lived assets
    		   153,000                                                                                     
      stock-based compensation
    		30,885,000 36,071,000 25,930,000 26,346,000 23,023,000 25,354,000 19,113,000 24,306,000 40,478,000 24,900,000 16,661,000 25,856,000 37,337,000 24,622,000 19,759,000 23,166,000 33,966,000 28,035,000 34,653,000 19,279,000 55,655,000 16,154,000 13,982,000 15,855,000 13,139,000 15,079,000 12,529,000 12,296,000 9,742,000 9,283,000 9,305,000                                                          
      non-cash lease expense
    		6,044,000 6,070,000 6,096,000 6,350,000 7,168,000 7,179,000 6,764,000 7,501,000 7,495,000 7,249,000 6,731,000 6,384,000 5,488,000 5,058,000 1,385,000 1,380,000 1,366,000 1,365,000 1,221,000 1,223,000 1,224,000 1,209,000 1,174,000                                                                  
      acquired in-process research and development technology
    		6,249,000   19,500,000 11,000,000 750,000 19,500,000 0 91,000,000 1,000,000 36,500,000                                                                              
      other
    		1,356,000 -5,831,000 -4,786,000 -4,379,000 -17,171,000 -1,282,000 9,206,000 -4,425,000 -4,196,000 -4,433,000 -3,743,000 -7,915,000 3,031,000 2,779,000 1,580,000 -12,428,000 13,040,000 16,253,000 6,578,000 1,426,000 883,000 1,614,000 -888,000     -935,000 -933,000 -2,212,000 1,722,000 59,000 384,000 466,000 680,000 -1,129,000 -243,000 336,000 -1,474,000 -11,000 245,000 456,000 637,000 559,000 987,000 1,140,000 1,475,000 1,544,000 1,601,000 1,909,000 1,733,000 1,539,000 1,084,000 1,062,000 1,304,000 1,164,000 1,855,000 1,304,000 478,000 819,000 762,000 715,000 938,000 998,000 426,000 -161,000 356,000 -63,000 417,000 380,000 212,000 240,000 229,000 172,000 145,000 202,000 242,000 175,000 135,000 156,000 157,000 172,000 117,000 203,000 173,000 -508,000 562,000 134,000 
      changes in operating assets and liabilities:
    		                                                                                        
      trade receivables
    		-17,370,000 -10,718,000 -16,119,000  127,025,000 -156,047,000 -3,170,000 11,181,000 -15,487,000 861,000 -19,178,000 -41,000 20,197,000 -45,100,000 91,793,000 -102,200,000 -7,811,000 5,377,000 -17,690,000 4,604,000 -45,060,000 16,256,000 -18,270,000 50,733,000 -72,247,000 10,129,000 55,101,000                                                              
      inventory
    		-4,149,000 2,639,000 -71,000 2,762,000 -384,000 1,360,000 1,715,000 1,526,000 -1,688,000 -4,445,000 -8,370,000 -1,847,000 -1,514,000 -4,802,000 -3,520,000 13,747,000 -18,936,000 -5,930,000 -2,090,000 -8,431,000 -6,417,000 -2,354,000 -4,695,000 -2,203,000 -1,014,000 -2,209,000 -305,000 595,000 -2,062,000 -808,000 -906,000 -851,000 -381,000 -2,121,000 34,000 -46,000 -484,000 -336,000 144,000 -494,000 486,000 -15,000 -212,000 1,495,000 -850,000 -340,000 204,000 -1,126,000 -1,083,000 -401,000 -280,000                                      
      prepaid expenses and other assets
    		47,649,000 -104,706,000 20,320,000 94,147,000 -96,728,000 23,585,000 10,075,000 -32,254,000 -6,118,000 -1,824,000 10,372,000 6,907,000 -9,141,000 -22,420,000 -3,605,000 -15,623,000 -11,956,000 -14,168,000 1,872,000 -9,963,000 3,086,000 -16,091,000 -2,863,000                  -1,061,000 2,799,000 -1,846,000  -3,060,000                                            
      accrued collaboration liabilities
    		903,000 -3,964,000 4,605,000 854,000 1,347,000 1,479,000 -3,829,000 264,000 -2,191,000 5,136,000 -1,864,000 1,911,000 -11,713,000 998,000 -54,261,000               -261,000 -1,000,000 -163,000 1,218,000                                                        
      accounts payable and other liabilities
    		17,755,000 -63,508,000 8,501,000 2,243,000 26,393,000 -16,275,000 -34,247,000 46,777,000 192,000 5,154,000 1,123,000 19,127,000 -11,188,000 10,527,000 7,376,000 7,278,000 18,977,000 28,697,000 138,000 -42,000 50,889,000 2,393,000 -2,131,000                                                                  
      net cash from operating activities
    		290,322,000 48,993,000 211,437,000 240,263,000 271,338,000 119,548,000 68,822,000 10,571,000 117,367,000 120,978,000 84,408,000 73,694,000 110,071,000 31,130,000 147,719,000 96,452,000 83,307,000 181,501,000 39,544,000 33,293,000 17,938,000 101,677,000 56,074,000 158,021,000 75,614,000 131,728,000 161,593,000 104,591,000 164,552,000 74,769,000 71,808,000 53,353,000 37,865,000 5,535,000 68,858,000 83,714,000 -6,435,000 -25,879,000 154,896,000 -35,433,000 -34,233,000 -26,833,000 -45,086,000 -49,976,000 -58,006,000 -55,337,000 -72,086,000 -47,329,000 -56,995,000 -40,034,000 -54,415,000 -38,736,000 -34,053,000 -35,391,000 -14,966,000 -29,174,000 -43,267,000 -43,516,000 -43,276,000 21,254,000 -43,827,000 -24,736,000 -53,739,000 -50,750,000 90,706,000 -12,425,000 -42,122,000 153,821,000 -56,391,000 -67,969,000 -39,218,000 -24,914,000 -39,356,000 -49,269,000 44,800,000 10,124,000 -34,251,000 -31,246,000 10,034,000 -6,177,000 -32,645,000 24,746,000 -32,285,000      
      capex
    		-1,482,000 -2,838,000 -2,952,000 -3,977,000 -8,197,000 -6,570,000 -9,691,000 -13,135,000 -9,373,000 -5,937,000 -12,024,000 -1,717,000 -9,970,000 -12,337,000 -5,609,000 -18,364,000 -14,479,000 -20,211,000 -13,557,000 -14,291,000 -6,091,000 -6,641,000 -2,480,000 0 -2,059,000 -1,209,000 -2,307,000 0 -15,221,000 -12,235,000 -2,947,000 -17,694,000 -1,137,000 -1,504,000 -808,000 -587,000 -33,000 -401,000 -682,000 -333,000 -20,000 -63,000 -31,000 -22,000 -108,000 40,000 -384,000 -92,000 -677,000 -673,000 -729,000 -1,189,000 -1,019,000 -437,000 -72,000 -279,000 -144,000 -163,000 -405,000 -330,000 -650,000 -579,000 -252,000 -4,316,000 -750,000 -444,000 -398,000 -1,207,000 -2,391,000 -6,171,000 -5,363,000 -3,249,000 -4,749,000 -5,761,000 -3,640,000 -3,273,000 -1,540,000 -4,740,000 -2,057,000 -3,238,000 -2,859,000 -4,274,000 -3,986,000      
      free cash flows
    		288,840,000 46,155,000 208,485,000 236,286,000 263,141,000 112,978,000 59,131,000 -2,564,000 107,994,000 115,041,000 72,384,000 71,977,000 100,101,000 18,793,000 142,110,000 78,088,000 68,828,000 161,290,000 25,987,000 19,002,000 11,847,000 95,036,000 53,594,000 158,021,000 73,555,000 130,519,000 159,286,000 104,591,000 149,331,000 62,534,000 68,861,000 35,659,000 36,728,000 4,031,000 68,050,000 83,127,000 -6,468,000 -26,280,000 154,214,000 -35,766,000 -34,253,000 -26,896,000 -45,117,000 -49,998,000 -58,114,000 -55,297,000 -72,470,000 -47,421,000 -57,672,000 -40,707,000 -55,144,000 -39,925,000 -35,072,000 -35,828,000 -15,038,000 -29,453,000 -43,411,000 -43,679,000 -43,681,000 20,924,000 -44,477,000 -25,315,000 -53,991,000 -55,066,000 89,956,000 -12,869,000 -42,520,000 152,614,000 -58,782,000 -74,140,000 -44,581,000 -28,163,000 -44,105,000 -55,030,000 41,160,000 6,851,000 -35,791,000 -35,986,000 7,977,000 -9,415,000 -35,504,000 20,472,000 -36,271,000      
      cash flows from investing activities:
    		                                                                                        
      purchases of marketable securities
    		-189,370,000 -101,485,000 -186,701,000 -305,383,000                                                 -199,303,000 -46,853,000 -113,368,000 -26,633,000 -21,144,000 -129,421,000 -60,015,000 -26,131,000 -37,623,000 -80,000,000 -23,563,000 -39,277,000 -78,869,000 -38,972,000 -4,048,000 3,665,000 3,660,000 -4,347,000 -4,932,000 -30,726,000 -64,897,000 -46,638,000 -61,556,000 -55,143,000 -8,598,000 -12,821,000 -15,180,000          
      proceeds from maturities and sales of marketable securities
    		221,506,000 353,104,000 258,917,000 226,159,000                                                                                     
      purchases of property, equipment and other
    		-1,482,000 -2,838,000 -2,952,000 -3,977,000 -8,197,000 -6,570,000 -9,691,000 -13,135,000 -9,373,000 -5,937,000 -12,024,000 -1,717,000 -8,043,000 -12,337,000 -5,609,000 -15,960,000 -14,497,000 -20,211,000 -13,557,000 -14,290,000 -6,130,000 -6,964,000 -2,961,000                                                                  
      net cash from investing activities
    		25,405,000 248,031,000 49,764,000 -93,201,000 -217,147,000 81,772,000 111,793,000 61,737,000 34,685,000 -73,785,000 -49,592,000 -245,782,000 -68,951,000 -135,142,000 -74,539,000 -13,055,000 -21,239,000 -70,845,000 62,255,000 -29,509,000 -207,600,000 73,274,000 32,620,000 -130,201,000 -206,460,000 -142,929,000 -107,657,000 -142,799,000 -63,251,000 -66,267,000 -25,533,000 -18,833,000 -26,591,000 46,716,000 34,503,000 -60,410,000 -12,128,000 -123,825,000 -19,685,000 24,009,000 -31,512,000 7,685,000 49,895,000 30,176,000 11,105,000 44,689,000 60,360,000 59,505,000 18,026,000 467,000 66,353,000 -99,629,000 -141,206,000 33,643,000 -52,278,000 37,375,000 32,559,000 -89,895,000 -31,502,000 6,394,000 -15,192,000 -38,382,000 27,611,000 -8,151,000 -69,391,000 -34,557,000 -223,000  50,054,000 8,720,000 29,271,000 7,122,000 4,904,000 9,909,000 -24,954,000 -44,038,000 21,257,000 -31,444,000 32,524,000 6,738,000 -29,639,000 -24,121,000 10,953,000 -179,000   72,000  
      cash flows from financing activities:
    		                                                                                        
      payments for repurchases of common stock
    		-104,035,000 -301,924,000 -283,934,000 -190,412,000 -11,927,000 -264,319,000 -185,375,000 -209,296,000 -216,843,000                                                                                
      proceeds from issuance of common stock under the equity incentive plan and stock purchase plan
    		   18,823,000 19,789,000                                                                                    
      taxes paid related to net share settlement of equity awards
    		-3,377,000 -40,502,000 -22,516,000 -16,445,000 -2,166,000 -13,026,000 -6,988,000 -5,986,000 -9,747,000 -10,832,000 -2,557,000 -7,209,000 -4,927,000 -6,478,000 -4,686,000 -24,059,000 -5,636,000 -3,972,000 -5,441,000 -23,898,000 -5,179,000 -19,148,000 -1,793,000 -6,535,000 -935,000 -854,000 -1,580,000 -4,369,000 -229,000 -847,000 -2,129,000 -3,551,000 -681,000 -788,000 -1,543,000                                                      
      net cash from financing activities
    		-103,860,000 -316,343,000 -294,823,000 -188,034,000 5,696,000 -262,422,000 -184,048,000 -206,173,000 -219,673,000 -124,792,000 4,586,000 -2,003,000 -2,038,000 4,422,000 205,000 -17,994,000 -2,881,000 8,724,000 -2,650,000 -18,694,000 -3,435,000 -5,148,000 2,145,000 -3,000,000 3,274,000 7,053,000 5,226,000 -1,144,000 3,915,000 7,174,000 -254,000 -713,000 2,871,000 -100,218,000 -71,868,000 17,163,000 -45,000 2,649,000 37,000 7,416,000 149,438,000 -3,890,000 -217,000 130,000 -374,000 449,000 65,287,000 -214,000 -789,000 109,000 -10,775,000 -371,000 415,924,000 -578,000 63,453,000 -155,000 1,639,000 6,640,000 179,389,000 -25,550,000 -2,842,000 162,029,000 -2,376,000 -24,873,000 -3,657,000 -1,531,000 -3,928,000 -3,676,000 -4,480,000 12,413,000 -3,627,000 12,073,000 70,354,000 1,139,000 682,000 101,915,000 -2,194,000 8,569,000 1,054,000 5,905,000 47,477,000 42,985,000 4,566,000 34,224,000    11,626,000 
      net increase in cash and cash equivalents
    		      -3,433,000 -133,865,000                           31,493,000 40,467,000   135,248,000 -4,008,000 83,693,000 -23,038,000 4,592,000   -10,199,000 53,561,000 11,962,000   1,163,000 -138,736,000   -3,791,000 8,046,000 -9,069,000 -126,771,000 104,611,000 2,098,000 -61,861,000       183,468,000   -13,574,000 -5,869,000   20,470,000 67,669,000 -15,174,000 -54,084,000 43,630,000 6,461,000 -14,811,000        
      cash and cash equivalents at beginning of period
    		0 0 217,374,000 0 0 0 262,994,000 0 0                            0 0 141,634,000  0 0 80,395,000  0 0 103,978,000  0 0 170,069,000                                      
      cash and cash equivalents at end of period
    		211,867,000 -19,319,000 183,752,000 -40,972,000 59,887,000 -61,102,000 259,561,000 -133,865,000 -67,621,000                            -18,608,000 -147,055,000 276,882,000  83,693,000 -23,038,000 84,987,000  -47,275,000 -10,199,000 157,539,000  -39,758,000 -39,458,000 171,232,000                                      
      supplemental cash flow disclosures:
    		                                                                                        
      non-cash operating activities:
    		                                                                                        
      right-of-use assets obtained in exchange for lease obligations
    		   0 0   3,011,000 28,000   33,977,000 1,595,000   0 0 0 4,893,000 2,193,000 0 1,248,000 576,000                                                                  
      proceeds from issuance of common stock under the equity incentive plans and stock purchase plan
    		                                                                                        
      net decrease in cash and cash equivalents
    		 -19,319,000 -33,622,000 -40,972,000 59,887,000                            14,145,000                                                  -16,721,000      
      proceeds from issuance of common stock under the equity incentive plans
    		  11,627,000                                                                                      
      deferred taxes
    		              15,318,000 14,164,000 9,565,000 26,188,000 -3,388,000 -538,000 -6,990,000 12,665,000 10,128,000                                                                  
      trade receivable
    		                                                                                        
      cash paid for taxes
    		                                                                                        
      impairment of right-of-use assets
    		                                                                                        
      non-cash investing activity:
    		                                                                                        
      unpaid liabilities incurred for purchases of in-process research and development technology
    		                                                                                        
      depreciation
    		    7,454,000 7,329,000 6,378,000 6,526,000 6,296,000 6,040,000 6,855,000    4,490,000 1,931,000 4,804,000 3,668,000 3,227,000 2,410,000 2,355,000 2,201,000 2,175,000                                                                  
      purchases of investments
    		     -108,686,000 -138,468,000 -78,621,000 -182,519,000 -329,491,000 -311,837,000 -371,305,000 -387,320,000 -355,546,000 -336,545,000 -279,791,000 -388,474,000 -357,291,000 -331,612,000 -203,294,000 -433,821,000 -181,649,000 -251,505,000 -294,984,000 -369,430,000 -278,399,000 -239,869,000 -189,528,000 -141,292,000 -110,475,000 -116,537,000 -71,044,000 -93,237,000 -30,315,000 -124,494,000 -110,678,000 -59,113,000 -150,161,000 -49,235,000 -24,300,000 -73,475,000 -32,935,000 -13,282,000 -10,291,000 -26,957,000 -46,343,000 -35,937,000 -13,207,000 -29,017,000 -51,594,000 -96,157,000                                      
      proceeds from maturities and sales of investments
    		     215,278,000 268,452,000 153,493,000 311,077,000 263,143,000 310,769,000 237,990,000 326,412,000 232,741,000 267,615,000 282,696,000 381,732,000 306,657,000 407,424,000  232,351,000 261,887,000 287,086,000                                                                  
      proceeds from issuance of common stock under equity incentive plans
    		      8,315,000    7,143,000  2,889,000 10,900,000 4,891,000   12,696,000 2,791,000    3,938,000                                                                  
      deferred revenue
    		         162,000 -707,000 647,000 -1,299,000 -662,000 -1,169,000 -426,000 2,088,000 -4,076,000 13,422,000 -5,063,000 -5,647,000 809,000 8,850,000     1,819,000 -7,458,000 8,562,000 -2,652,000 -6,965,000 -7,449,000 -6,980,000 35,139,000 5,247,000 56,043,000 -3,333,000 198,802,000 1,000 0 -7,000 -2,576,000 1,264,000 192,000 -116,000 -207,000 433,000 -490,000 -7,704,000 -7,110,000 -7,814,000 -7,813,000 -7,813,000 -18,480,000 -69,366,000 -124,666,000 -25,099,000 -25,397,000 35,256,000 -42,911,000 -8,910,000 -26,380,000 -30,829,000 105,768,000 14,195,000 -3,357,000 189,116,000 -27,019,000 -27,537,000 -1,780,000 233,000 -14,168,000 -24,778,000 42,832,000 41,780,000 -12,712,000 -16,354,000 26,753,000 12,873,000 -9,222,000 18,102,000 6,261,000      
      proceeds from issuance of common stock under equity incentive and stock purchase plans
    		       9,109,000 6,917,000       6,065,000    5,204,000 1,744,000                                                                    
      net increase in cash, cash equivalents and restricted cash equivalents
    		          39,402,000     65,403,000 59,187,000 119,380,000 99,149,000                                                                      
      cash, cash equivalents and restricted cash equivalents at beginning of period
    		          502,677,000 0 0 0 663,891,000 0 0 0 320,772,000                                                                      
      cash, cash equivalents and restricted cash equivalents at end of period
    		          542,079,000 -174,091,000 39,082,000 -99,590,000 737,276,000 65,403,000 59,187,000 119,380,000 419,921,000                                                                      
      non-cash investing activities:
    		                                                                                        
      accounts receivable for unsettled investment sales
    		                                                                                        
      net increase in cash, cash equivalents, and restricted cash equivalents
    		            39,082,000 -99,590,000 73,385,000                                                                          
      unpaid liabilities incurred for purchases of property and equipment
    		            -1,927,000   -2,404,000 18,000   -1,000 39,000 323,000 481,000                                                                  
      unpaid liabilities incurred in asset acquisition
    		            0   -5,000,000 0                                                                        
      unpaid liabilities incurred for unsettled investment purchases
    		                                                                                        
      proceeds from sale of property and equipment
    		                           0    150,000 0 10,000 4,000 5,000 -20,000 5,000 107,000 46,000 5,000 656,000 639,000 106,000 5,000 5,000 276,000 103,000             11,000 -7,000 175,000                          
      proceeds from sales and maturities of investments
    		                                                                                        
      net increase in cash, cash equivalents and restricted cash
    		                    -193,097,000 169,803,000 90,839,000  -127,572,000 -4,148,000 59,162,000 -39,352,000 105,216,000 15,676,000 46,021,000                                                          
      cash, cash equivalents and restricted cash at beginning of period
    		                    0 0 268,137,000  0 0 315,875,000 0 0 0 188,314,000                                                          
      cash, cash equivalents and restricted cash at end of period
    		                    -193,097,000 169,803,000 358,976,000  -127,572,000 -4,148,000 375,037,000 -39,352,000 105,216,000 15,676,000 234,335,000                                                          
      unpaid liabilities incurred to acquire investments
    		                                                                                        
      principal repayments of debt
    		                                                                                        
      supplemental cash flow disclosure:
    		                                                                                        
      cash paid for interest
    		                                                                                        
      non-cash activities:
    		                                                                                        
      property and equipment deemed to have been acquired in build-to-suit lease
    		                                                                                        
      401(k) matching contributions made in common stock
    		                        528,000 1,082,000 2,469,000 464,000 509,000                                                            
      amortization and other changes in right-of-use assets
    		                        704,000                                                                
      deferred income taxes
    		                        23,272,000                                                                
      gain on other equity investments
    		                        0   0 0 0 -209,000 0                                                         
      accretion of investments, net and other
    		                        -1,051,000 -1,504,000 -1,415,000                                                              
      other receivables
    		                        -1,192,000 -5,080,000 8,741,000                     1,230,000 -962,000 -344,000 -1,114,000 -44,000 -424,000 -364,000 27,870,000 -25,536,000 1,709,000 -592,000 125,000 1,410,000 -1,278,000 1,062,000 4,774,000 -470,000 -4,333,000 -1,447,000 -2,255,000 434,000 184,000 2,686,000 -3,103,000 -743,000 -901,000 957,000 18,385,000 -18,674,000 -2,151,000 4,422,000 1,313,000 -454,000 -2,163,000 8,216,000 -8,400,000   1,073,000 792,000  
      current portion of unbilled collaboration revenue
    		                        -490,000                                                                
      prepaid expenses and other current assets
    		                        -1,643,000 1,299,000 871,000 500,000 -1,952,000 -3,477,000 1,900,000 -738,000 -3,579,000 1,930,000 -881,000 1,732,000 -2,491,000 134,000 -985,000        -359,000 2,529,000 -1,719,000 4,981,000 -4,757,000 128,000 -1,638,000 14,000 -268,000 12,075,000 -2,007,000 1,764,000 -1,279,000 2,891,000 -1,528,000 1,974,000 -3,403,000 -4,429,000 -1,739,000 -430,000 -740,000 -953,000 1,441,000 -512,000 -1,538,000 708,000 -277,000 -2,481,000 -915,000 1,418,000 -1,349,000 -1,200,000 486,000          
      other long-term assets
    		                        -1,505,000 65,000 -4,854,000 -544,000 -545,000 349,000 -346,000 -259,000 170,000 538,000 -19,000                                                      
      accounts payable
    		                        -2,731,000 1,317,000 -1,294,000 2,104,000 287,000 -1,352,000 -183,000 3,587,000 -1,049,000 2,388,000 -1,916,000                                                      
      accrued compensation and benefits
    		                        7,569,000 1,594,000 -9,592,000 4,859,000 5,745,000 782,000 -317,000 1,159,000 4,359,000 1,065,000 -5,844,000                                                      
      accrued clinical trial liabilities
    		                        6,621,000 654,000 4,824,000 -727,000 2,157,000 1,450,000 -4,498,000 3,668,000 1,501,000 202,000 347,000                                                      
      rebates and fees due customers
    		                        -491,000 -2,435,000 4,754,000 3,265,000                                                             
      accrued collaboration liability
    		                        126,000 291,000 137,000 -978,000        -18,710,000 1,717,000 2,319,000 3,736,000                                                  
      current and long-term deferred revenue
    		                        -1,064,000 5,969,000 -1,313,000                                                              
      long-term portion of lease liabilities
    		                        -690,000 -740,000 7,517,000 -251,000                                                             
      other current and long-term liabilities
    		                        8,231,000 -13,460,000 21,169,000 5,548,000 -13,485,000 8,631,000 1,533,000 -2,289,000 4,742,000 -3,469,000 10,926,000                                                      
      purchases of property and equipment
    		                        -2,059,000 -1,209,000 -2,307,000     -17,694,000 -1,137,000 -1,504,000 -808,000 -587,000 -33,000 -401,000 -682,000 -333,000 -20,000 -63,000 -31,000 -22,000 -108,000 40,000 -384,000 -92,000 -677,000 -673,000 -729,000 -1,189,000 -1,019,000 -437,000 -72,000 -279,000 -144,000 -163,000 -405,000 -330,000 -650,000 -579,000 -252,000 -4,316,000 -750,000 -444,000 -398,000 -1,207,000 -2,391,000 -6,171,000 -5,363,000 -3,249,000 -4,749,000 -5,761,000 -3,640,000 -3,273,000 -1,540,000 -4,740,000 -2,057,000 -3,238,000 -2,859,000 -4,274,000 -3,986,000      
      proceeds from maturities of investments
    		                        163,628,000 128,971,000 129,820,000 49,622,000 91,256,000 52,444,000 87,504,000 70,255,000 65,442,000 78,386,000 122,507,000 50,850,000 42,295,000 28,232,000 30,108,000 48,595,000 35,903,000 40,028,000 54,410,000 40,385,000 31,248,000 90,947,000 90,311,000 73,701,000 41,581,000 52,793,000 157,096,000                                      
      proceeds from sale of investments
    		                        1,401,000 6,978,000 4,699,000 1,000 1,698,000 3,999,000 6,238,000 0 0 0 37,294,000 0 2,249,000 0 17,000                                                  
      proceeds from other equity investments
    		                        0   0 0 0 209,000 0                                                         
      proceeds from exercise of stock options
    		                        4,221,000 3,773,000 6,817,000 1,686,000 3,840,000 4,675,000 1,875,000 1,023,000 3,552,000 3,305,000 9,675,000 16,031,000 7,089,000                                                    
      proceeds from employee stock purchase plan
    		                        0   1,552,000 0   1,815,000 0   1,708,000 0   294,000 0   509,000 1,000   535,000 0   389,000 1,000   747,000 0   1,010,000 0   1,676,000 0       1,825,000 1,000   1,516,000 0   1,083,000 0   978,000 0   0 
      principal payments on financing lease obligation
    		                        -12,000 -11,000 -11,000                                                              
      amortization and other right-of-use assets
    		                          -7,730,000                                                              
      unbilled collaboration revenue
    		                          -7,753,000    -38,014,000                                                          
      amortization of right-of-use assets
    		                                                                                        
      loss on extinguishment of debt
    		                               0 0   128,000                                                     
      amortization of debt discounts and debt issuance costs
    		                               0 0 93,000 89,000                                                      
      interest paid in kind
    		                               0                                                         
      payments on conversion of convertible notes
    		                                   -1,000                                                     
      changes in assets and liabilities:
    		                                                                                        
      trade and other receivables
    		                            70,324,000 -75,214,000 -10,755,000 8,402,000 -46,660,000 -9,122,000 6,541,000 48,921,000 -73,562,000 -7,423,000 -4,938,000 -1,680,000 288,000 -546,000 1,292,000 -160,000 312,000 -577,000 -516,000                                          
      operating lease right-of-use assets
    		                                                                                        
      purchases of property and equipment and other
    		                            -15,221,000 -12,235,000 -2,947,000                                                          
      supplemental cash flow disclosure - non-cash investing and financing activity:
    		                                                                                        
      property and equipment deemed to have been acquired under build-to-suit lease
    		                                                                                        
      unpaid liabilities incurred to acquire property and equipment
    		                                                                                        
      changes in warrant fair value
    		                                                                                        
      purchase of restricted cash and investments
    		                               -4,500,000 -5,000,000 -2,646,000 -3,504,000 -4,500,000 0 -2,146,000 -2,004,000 -3,034,000 1,568,000 -1,500,000 -2,684,000 41,000 -3,541,000 -4,139,000 -504,000 -2,300,000 -1,000 -3,280,000 -504,000                                      
      proceeds from maturities of restricted cash and investments
    		                               4,000,000 5,000,000 2,146,000 3,504,000 4,500,000 0 646,000 2,004,000 3,035,000 4,507,000 1,499,000 10,748,000 -43,000 9,620,000 4,179,000 6,598,000 1,300,000 6,100,000 3,221,000 6,647,000                                      
      proceeds from issuance of common stock
    		                                      37,000 -2,000    -3,000 0 0 75,646,000     0     0 30,000 179,347,000                      49,614,000 0 8,854,000     8,247,000 
      cash and cash equivalents at beginning of year
    		                                 0 151,686,000                                                      
      cash and cash equivalents at end of year
    		                                 -47,967,000 183,179,000                                                      
      stock-based compensation expense
    		                                5,289,000 5,027,000 4,713,000 4,566,000 3,603,000 3,558,000 11,185,000 6,557,000 12,026,000 1,734,000 1,660,000 1,552,000 714,000 3,982,000 3,758,000 3,528,000 2,898,000 2,926,000 2,679,000 2,611,000 1,900,000 1,990,000 2,332,000 2,690,000 2,974,000 2,832,000 3,603,000 4,368,000 5,463,000 4,755,000 6,526,000 5,394,000 5,939,000 6,481,000 5,092,000 5,826,000 5,788,000 5,619,000 5,674,000 5,218,000 5,229,000 5,178,000 4,543,000 4,458,000 4,076,000 4,443,000 4,636,000          
      repayment of convertible notes and term loan payable
    		                                0                                                        
      payment on conversion of convertible notes
    		                                                                                        
      construction-in-progress deemed to have been acquired under build-to-suit lease
    		                                0                                                        
      issuance of common stock in settlement of convertible notes
    		                                                                                        
      accrual of interest paid in kind
    		                                 -13,893,000 2,068,000 2,069,000 2,031,000 1,972,000 1,936,000 1,927,000                                                 
      gain on sale of other equity investments
    		                                                                                        
      proceeds from sale of other equity investments
    		                                                                                        
      principal payments on debt
    		                                  -80,000,000     0 0 -4,164,000 -217,000 -376,000 -375,000 -479,000 -10,479,000 -796,000 -792,000 -791,000 -10,791,000                                      
      cash flows from operating activities:
    		                                                                                        
      gain on sale of business and other equity investment
    		                                       -17,000                                                 
      changes in the fair value of warrants
    		                                           76,000 -62,000                                            
      proceeds from sale of business and other equity investments
    		                                                                                        
      redemption of convertible notes
    		                                                                                        
      accretion of debt discount and debt issuance costs
    		                                    -2,417,000                                                    
      gain on sale of equity investment
    		                                         0 -95,000                                              
      change in the fair value of warrants
    		                                        0 0 549,000                                              
      other long term assets
    		                                    436,000 -142,000 241,000                                                  
      accounts payable, accrued compensation and benefits, and other accrued liabilities
    		                                    4,527,000 8,956,000 5,333,000                                                  
      clinical trial liabilities
    		                                    -794,000 -454,000 -1,936,000  -2,784,000 1,596,000 -10,569,000  3,735,000 2,249,000 4,160,000                                          
      other long-term liabilities
    		                                    -322,000 -235,000 -258,000 -306,000 -464,000 -615,000 -288,000 -671,000 -277,000 -250,000 -229,000 -1,160,000 -156,000 -231,000 -143,000 -1,512,000 210,000 -199,000 -87,000 -404,000 -198,000 -328,000 -232,000 -7,064,000 -227,000 -877,000 -152,000 -6,581,000 402,000 402,000 483,000 -4,718,000 1,084,000 499,000 831,000 505,000 1,164,000 1,667,000 1,097,000 1,310,000 1,326,000 1,670,000 1,709,000 1,725,000 1,801,000 1,341,000 1,612,000 1,157,000 618,000 550,000 550,000 250,000 
      proceeds from sale of equity investments
    		                                                                                        
      supplemental cash flow disclosure - non-cash financing activity:
    		                                                                                        
      restructuring liability
    		                                     130,000 -1,057,000 -1,449,000 -2,410,000 -297,000 -3,024,000 403,000 298,000 -1,762,000 -1,241,000 -430,000 -1,971,000 -971,000 -2,378,000 8,733,000 -1,494,000 -130,000 -1,865,000 3,583,000   -1,478,000                              
      proceeds from equity investment
    		                                                                                        
      accretion of debt discount
    		                                      5,285,000 4,840,000 5,303,000 7,216,000 7,675,000 7,708,000 7,510,000 7,328,000 6,988,000 6,845,000 6,652,000 6,479,000 6,314,000 6,128,000 4,147,000 2,284,000 2,193,000 2,089,000 2,084,000 492,000 3,324,000                              
      accounts payable, accrued compensation, and other accrued liabilities
    		                                       -1,114,000 -567,000 3,821,000 -3,416,000  -6,695,000 5,349,000 -10,254,000                                          
      clinical trial liability
    		                                               -84,000 5,636,000                                        
      proceeds from sale of business and other equity investment
    		                                       0                                                 
      proceeds from exercise of stock options and warrants
    		                                       7,124,000    0 0 0 120,000 47,000 3,000 6,000 16,000 28,000    731,000 4,079,000 3,832,000 3,794,000 1,630,000 50,000 133,000 871,000 269,000 2,000 0 2,000 11,000 5,000 288,000 6,000 480,000 1,429,000 3,211,000 3,181,000  159,000 798,000 1,562,000          
      non-cash financing activity:
    		                                                                                        
      issuance of warrants in connection with amendment to convertible notes
    		                                           0 0 0 2,762,000                                          
      restructuring charge for property and equipment
    		                                                                                        
      proceeds from sale of equity investment
    		                                         0 95,000                                              
      gain on sale of business
    		                                           0                 0 -3,297,000 -4,500,000                          
      other assets
    		                                              -5,000     17,000 -1,759,000 -108,000 -116,000 -296,000 469,000 118,000 114,000 -87,000 -19,000 -1,712,000 11,000 5,313,000 370,000 371,000 370,000 416,000 345,000 -3,631,000 95,000 427,000 -118,000 -486,000 2,000 -30,000 702,000 106,000 -134,000 -11,000 67,000 11,000 -1,089,000     -3,000 
      accounts payable and other accrued liabilities
    		                                               9,343,000 -1,031,000 5,851,000 -5,472,000                      7,269,000                
      proceeds from sale of business
    		                                           0                   4,500,000                          
      proceeds from debt issuance
    		                                                                                        
      gain on warrants
    		                                              -1,739,000                                          
      restructuring (credit) charge for property and equipment
    		                                                   -63,000 38,000 16,000 -195,000                                  
      gain on sale of property and equipment
    		                                                                                        
      gain on sale of businesses
    		                                                                                        
      proceeds from sale of businesses
    		                                                                                        
      issuance of common stock for settlement of convertible loan, including accrued interest
    		                                                                                        
      restructuring credit for property and equipment
    		                                                                                        
      net gain on sale of property and equipment
    		                                                                                        
      accounts payable and other accrued expenses
    		                                                    3,079,000 2,937,000 -2,736,000 -3,330,000 -2,411,000 -2,719,000 2,905,000 -8,234,000 2,416,000 -9,776,000 6,150,000 7,703,000 4,401,000 3,925,000 -7,021,000 1,173,000 3,796,000 -303,000 2,297,000    6,667,000 8,100,000 2,258,000 614,000 1,192,000 2,593,000 1,225,000 3,326,000 -6,789,000      
      proceeds from sales of property and equipment
    		                                                    18,000 12,000 847,000                                  
      proceeds on sale of business
    		                                                           400,000 0                            
      increase in restricted cash and investments
    		                                                            0    0 108,000 -837,000                      
      proceeds from maturities of marketable securities
    		                                                    95,219,000 80,789,000 60,315,000 7,556,000 50,837,000 39,689,000 26,718,000 32,469,000 23,070,000 38,059,000 33,971,000 43,769,000 635,000 2,425,000 2,938,000 9,000 7,871,000 9,002,000 34,299,000 15,152,000 49,732,000 57,095,000 34,360,000 8,133,000 26,315,000 19,750,000 45,443,000          
      proceeds from convertible notes
    		                                                                                        
      proceeds from note payable and bank obligations
    		                                                        0    0                            
      principal payments on notes payable and bank obligations
    		                                                    -788,000 -1,648,000 -1,646,000 -1,631,000 -2,440,000 -798,000 -3,752,000 -30,690,000 -2,892,000 -2,734,000 -3,247,000 -31,820,000 -3,659,000 -3,656,000 -3,930,000 -5,699,000 -4,485,000 -3,636,000 -3,633,000 -2,857,000 -2,973,000 -3,813,000 -2,499,000   -33,488,000 -2,842,000 -1,720,000 -2,179,000 -1,724,000 -3,678,000      
      cash and cash equivalents, at beginning of period
    		                                                    0 0 74,257,000  0 0 97,440,000  0 0 86,796,000  0 0 247,698,000  0 0 135,457,000  0 0 123,369,000  -15,143,000 0 96,471,000  0 0 78,105,000  0 0 111,828,000 0 
      cash and cash equivalents, at end of period
    		                                                    240,665,000 -2,326,000 70,466,000  -9,069,000 -126,771,000 202,051,000  -61,861,000 98,911,000 58,292,000  17,658,000 -48,513,000 201,425,000  -10,817,000 -46,836,000 121,883,000  35,719,000 -38,232,000 143,839,000  -30,317,000 -54,084,000 140,101,000  -14,811,000 43,437,000 61,384,000  9,069,000 -41,399,000 80,323,000 -13,516,000 
      decrease in restricted cash and investments
    		                                                        0 0 2,200,000                              
      proceeds from issuance of common stock, net of offering costs
    		                                                     46,000 64,990,000                                  
      proceeds from exercise of stock options and warrants, net of repurchases
    		                                                     197,000 109,000                                  
      consolidated net income
    		                                                       46,296,000 77,865,000   -17,865,000 -8,603,000 -22,613,000 -43,249,000 -28,834,000 -25,445,000 -46,942,000 -38,336,000                      
      impairment of property and equipment, net of proceeds from sales
    		                                                                                        
      loss on deconsolidation of symphony evolution, inc.
    		                                                               0 0                        
      purchases of investments held by symphony evolution, inc.
    		                                                               0 0 -13,000 -36,000 -106,000 -133,000 -173,000 -295,000 -444,000 -556,000 -611,000 -669,000 -745,000 -810,000 -40,440,000 -343,000 -351,000 -325,000        
      proceeds on sale of investments held by symphony evolution, inc.
    		                                                               0 0 2,339,000 2,158,000 3,876,000 4,036,000 5,370,000 3,657,000 8,241,000 6,534,000 6,854,000 4,804,000    4,102,000 3,854,000         
      proceeds on sale of property and equipment
    		                                                                                        
      proceeds on sale of businesses
    		                                                                                        
      decrease (increase) in restricted cash and investments
    		                                                                                        
      proceeds from sale of marketable securities
    		                                                           0 0 0 12,780,000 -7,027,000     27,171,000                    
      proceeds from issuance of stock, net of offering costs
    		                                                                                        
      proceeds from notes payable and bank obligations
    		                                                                   0 0       12,367,000 0 0 2,424,000 6,107,000 0        
      repayments, net from deconsolidation of symphony evolution, inc.
    		                                                               0 0                        
      cash and cash equivalents, at beginning of year
    		                                                                                        
      cash and cash equivalents, at end of year
    		                                                                                        
      impairment of assets due to restructuring
    		                                                        -131,000 388,000 122,000   7,000 2,474,000                          
      restructure liability
    		                                                                                        
      proceeds from sales of marketable securities
    		                                                                                        
      impairment of assets
    		                                                           846,000                             
      gain on sale of plant trait business and artemis pharmaceuticals
    		                                                                                        
      warrants issued in conjunction with deerfield financing agreement
    		                                                                   0 0                    
      accretion of deerfield implied interest
    		                                                                                        
      accrued restructuring liability
    		                                                                                        
      net decreases in cash and cash equivalents
    		                                                              -28,504,000  17,658,000 -48,513,000 -46,273,000                      
      amortization of intangibles
    		                                                                          72,000 98,000 210,000 240,000 272,000 271,000 271,000 272,000 272,000 278,000 168,000 167,000 166,000 166,000 
      proceeds on sale of plant trait business
    		                                                                                        
      proceeds on sale of artemis pharmaceuticals
    		                                                                                        
      (increase)/decrease in restricted cash and investments
    		                                                                                        
      proceeds from the issuance of common stock, net of offering costs
    		                                                                                        
      effect of foreign exchange rates on cash and cash equivalents
    		                                                                               -5,000 -4,000 -173,000 45,000     70,000 
      non-cash investing and financing activities:
    		                                                                                        
      loss attributed to noncontrolling interest
    		                                                                   -2,796,000 -2,681,000 -3,343,000 -3,896,000 -2,408,000 -8,184,000 -7,460,000 -6,589,000 -6,863,000 -5,546,000 -5,770,000 -3,518,000 -4,891,000 -5,086,000        
      proceeds from sale of equipment
    		                                                                           6,000 0            
      proceeds on sale of marketable securities
    		                                                                                        
      net cash provided (used) in investing activities
    		                                                                                        
      payments on capital lease obligations
    		                                                                           0 0 -8,000 -90,000 -249,000 -384,000 -634,000 -664,000      
      proceeds from purchase of noncontrolling interest by preferred shareholders in symphony evolution, inc., net of fees
    		                                                                           0 0   0 0        
      warrants issued in conjunction with the symphony evolution, inc. financing
    		                                                                                        
      changes in restricted cash and investments
    		                                                                    840,000 -361,000 1,905,000  840,000 990,000 -273,000              
      proceeds from sale of stock, net of offering costs
    		                                                                                        
      proceeds from employee stock purchase plans
    		                                                                    0                    
      effect of foreign exchange rate changes on cash and cash equivalents
    		                                                                        -183,000 -11,000 -58,000  14,000 37,000 18,000          
      loss on the sale of equipment
    		                                                                                        
      change in restricted cash and investments
    		                                                                           1,586,000 -216,000 1,119,000 559,000 840,000 1,231,000 727,000 560,000      
      amortization of intangible assets
    		                                                                        51,000                
      income from the sale of equipment
    		                                                                        7,000 1,000 5,000              
      proceeds from purchase of noncontrolling interest by preferred stockholders in symphony evolution, inc.
    		                                                                                        
      warrants issued in conjunction with the symphony evolution, inc. transaction
    		                                                                            0   5,684,000 0        
      proceeds from maturities of long term marketable securities
    		                                                                          2,020,000              
      acquired in-process research and development
    		                                                                                   25,981,000 0    
      cash paid for acquisitions, net of cash acquired
    		                                                                                        
      repayment of notes from stockholders
    		                                                                                   0 0 0 53,000 74,000 
      gain on the sale of equipment
    		                                                                            -3,000    0 -16,000 -122,000      
      proceeds from sale of investments held by symphony evolution, inc.
    		                                                                            6,106,000            
      principal payments on notes and bank obligations
    		                                                                                        
      related-party receivables
    		                                                                               0 3,000 15,000 27,000 28,000 40,000   65,000 
      stock compensation expense
    		                                                                                28,000 23,000 -16,000   42,000 33,000  
      non-cash portion of restructuring charge
    		                                                                                        
      prepaid expense and other current assets
    		                                                                                -1,249,000 -669,000 -925,000      
      cash received from acquisition, net of cash paid
    		                                                                                        
      proceeds on sale of equipment
    		                                                                                0 1,000 152,000      
      proceeds from maturities of short-term investments
    		                                                                                10,618,000 35,026,000 35,512,000 19,482,000 64,596,000 24,773,000 29,307,000 52,017,000 
      purchases of short-term investments
    		                                                                                -41,092,000 -15,596,000 -21,285,000      
      proceeds from exercise of stock options, net of repurchases
    		                                                                                426,000 609,000 54,000  542,000 1,268,000 721,000 8,000 
      income from discontinued operations
    		                                                                                        
      proceeds from sale of investments before maturity
    		                                                                                        
      proceeds from bank obligations
    		                                                                                   4,849,000 7,457,000   5,933,000 
      property and equipment acquired under capital leases
    		                                                                                        
      stock compensation expense, net of reversals
    		                                                                                       167,000 
      other current assets
    		                                                                                        
      cash from acquisition
    		                                                                                    0    
      changes in restricted cash
    		                                                                                        
      accrued merger and acquisition costs
    		                                                                                        
      change in restricted cash
    		                                                                                        
      principal payments on capital lease obligations
    		                                                                                        
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.